STERIS plc $STE Shares Sold by LaFleur & Godfrey LLC

LaFleur & Godfrey LLC lowered its stake in STERIS plc (NYSE:STE) by 12.5% in the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 26,338 shares of the medical equipment provider’s stock after selling 3,748 shares during the period. LaFleur & Godfrey LLC’s holdings in STERIS were worth $5,531,000 at the end of the most recent quarter.

Several other institutional investors have also recently bought and sold shares of STE. Western Wealth Management LLC acquired a new position in STERIS during the 1st quarter worth $25,000. Elevation Wealth Partners LLC boosted its position in STERIS by 1,130.0% in the 2nd quarter. Elevation Wealth Partners LLC now owns 123 shares of the medical equipment provider’s stock valued at $26,000 after buying an additional 113 shares during the last quarter. Meramec Financial Planners LLC acquired a new stake in shares of STERIS in the 1st quarter valued at $33,000. Trust Co. of Vermont acquired a new stake in shares of STERIS in the 2nd quarter valued at $41,000. Finally, Community Financial Services Group LLC increased its stake in shares of STERIS by 50.0% in the 3rd quarter. Community Financial Services Group LLC now owns 216 shares of the medical equipment provider’s stock valued at $45,000 after buying an additional 72 shares during the period. Institutional investors own 94.69% of the company’s stock.

STERIS Trading Down 0.0%

STE opened at $228.46 on Thursday. The firm has a 50 day simple moving average of $220.07 and a 200 day simple moving average of $225.49. STERIS plc has a fifty-two week low of $195.14 and a fifty-two week high of $269.44. The company has a market cap of $22.27 billion, a price-to-earnings ratio of 27.93 and a beta of 0.92. The company has a debt-to-equity ratio of 0.23, a current ratio of 1.91 and a quick ratio of 1.35.

STERIS (NYSE:STE) last announced its quarterly earnings data on Wednesday, August 5th. The medical equipment provider reported $2.59 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.49 by $0.10. STERIS had a net margin of 13.34% and a return on equity of 14.34%. The firm had revenue of $1.49 billion for the quarter, compared to analysts’ expectations of $1.49 billion. During the same period last year, the firm earned $2.34 earnings per share. The business’s revenue for the quarter was up 7.3% on a year-over-year basis. STERIS has set its FY 2027 guidance at 11.000-11.300 EPS. On average, sell-side analysts anticipate that STERIS plc will post 11.17 earnings per share for the current year.

STERIS Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Thursday, December 17th. Shareholders of record on Tuesday, November 17th will be given a dividend of $0.69 per share. The ex-dividend date is Tuesday, November 17th. This represents a $2.76 annualized dividend and a dividend yield of 1.2%. STERIS’s payout ratio is presently 33.74%.

Insider Buying and Selling at STERIS

In other news, Director Mohsen Sohi sold 4,058 shares of the stock in a transaction on Wednesday, August 12th. The stock was sold at an average price of $235.78, for a total value of $956,795.24. Following the transaction, the director owned 24,305 shares of the company’s stock, valued at $5,730,632.90. This represents a 14.31% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. 1.12% of the stock is currently owned by company insiders.

Analyst Upgrades and Downgrades

Several brokerages have recently issued reports on STE. UBS Group cut their price target on STERIS from $275.00 to $270.00 and set a “buy” rating on the stock in a research note on Friday, August 7th. Weiss Ratings reiterated a “hold (c)” rating on shares of STERIS in a report on Monday, August 24th. Wall Street Zen lowered STERIS from a “strong-buy” rating to a “buy” rating in a research report on Sunday, October 11th. Finally, Piper Sandler reissued an “overweight” rating and set a $275.00 price objective (up from $270.00) on shares of STERIS in a report on Friday, August 7th. Three research analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the company’s stock. According to MarketBeat.com, STERIS has a consensus rating of “Moderate Buy” and a consensus target price of $271.33.

STERIS Profile

STERIS plc (NYSE: STE) provides products and services designed to support infection prevention, procedural care and the safe manufacture of healthcare and life sciences products. Its offerings include surgical equipment and operating-room solutions, sterilization and decontamination systems, endoscopy products, cleaning and disinfection technologies, and related consumable products.

The company also provides outsourced sterilization and laboratory services through its Applied Sterilization Technologies business.